CCI-779 Isomer C

Details CCI-779 Isomer C CCI-779 Isomer C

2006-07-11

2006-07-11

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C540S456000

Reexamination Certificate

active

07074804

ABSTRACT:
Purified CCI-779 Isomer C is provided, as are pharmaceutical compositions and kits containing same.

REFERENCES:
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5661156 (1997-08-01), Holt et al.
patent: 6277983 (2001-08-01), Shaw et al.
patent: WO-95/28406 (1995-10-01), None
patent: WO-02/26746 (2002-04-01), None
patent: WO-02/28866 (2002-04-01), None
Steffan et al, Base Catalyzed Degradations of Rapamycin, Tetrahedron Letters, vol. 34, No. 23, pp. 3699-2702, (1993).
Skotnicki et al, Synthesis of Secorapamycin Esters and Amides1, Tetrahedron Letters, vol. 35, No. 2, pp. 197-200, (1994).
Sehgal, Sirolimus: A New Immunosuppressive Agent, Chapter 12.1, Principles of Drug Development in Transplantation and Autoimmunity, pp. 271-282, (1996).
Caufield et al, Structure-Activity Involving Modifications to the Macrolides FK-506 and Rapamycin, Current Pharmaceutical Design, vol. 1, No. 2, pp. 145-160, (1995).
Sehgal et al, Rapamycin: A Novel Immunosuppressive Macrolide, Medicinal Research Reviews, vol. 14, No. 1, pp. 1-22, (Jan. 1994).
Hughes et al, The Isolation, Synthesis and Characterization of An Isomeric Form of Rapamycin, Tetrahedron Letters, vol. 33, No. 33, pp. 4739-4742, (1992).

Affiliated with

Also associated with

Rating

CCI-779 Isomer C does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CCI-779 Isomer C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCI-779 Isomer C will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3554735